The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011

The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

Published:2018-01-20 Issue:4 Volume:36 Page:467-475
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Skedgel Chris^ORCID,Wranik Dominika^ORCID,Hu Min^ORCID

Funder

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-018-0610-0/fulltext.html

Reference43 articles.

1. Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, et al. Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff Proj Hope. 2006;25:337–47.

2. Bae G, Bae EY, Bae S. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. Health Policy Amst Neth. 2015;119:577–87.

3. Pan-Canadian Oncology Drug Review. About the pan-Canadian Oncology Drug Review [Internet]. 2011 [cited 2015 Feb 17]. Available from: http://www.pcodr.ca/wcpc/portal/Home/AboutpCODR?_afrLoop=2451339295194000&lang=en&_afrWindowMode=0&_adf.ctrl-state=20t18y0il_91 .

4. CADTH Common Drug Review. Procedure for the CADTH Common Drug Review [Internet]. 2014 [cited 2015 Feb 17]. Available from: http://www.cadth.ca/media/cdr/process/CDR_Procedure.pdf .

5. Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee Deliberative Framework [Internet]. 2011 [cited 2015 Feb 17]. Available from: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr_perc_deliberative_frame.pdf .

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices;Current Oncology;2024-04-28

2. The Use of Evidence to Design an Essential Package of Health Services in Pakistan: A Review and Analysis of Prioritisation Decisions at Different Stages of the Appraisal Process;International Journal of Health Policy and Management;2024-03-09

3. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada;PharmacoEconomics;2023-12-27

4. Impact of Oncology Drug Review Times on Public Funding Recommendations;Current Oncology;2023-08-18

5. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?;Value in Health;2023-07